Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Bioscience (RCUS) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer’s immunosuppressive mechanisms. This page provides investors and researchers with timely updates on the company’s developments in immuno-oncology, including advancements in its ATP-adenosine pathway research.
Access the latest press releases, clinical trial milestones, and financial disclosures in one centralized hub. Track updates on therapeutic candidates spanning small molecules and biologics, partnership announcements, and regulatory progress. Our curated news collection ensures you stay informed about RCUS’s efforts to address unmet needs in lung, colorectal, and pancreatic cancers.
Bookmark this page for real-time insights into Arcus Bioscience’s R&D pipeline, strategic initiatives, and industry positioning. Check back regularly for verified updates directly from corporate communications and trusted financial sources.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of stock options to a new employee, totaling 28,000 shares at a price of $34.74 each, reflecting the closing price as of November 8, 2021. This issuance is part of the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020. The company focuses on developing cancer therapies, with six investigational drugs currently in clinical studies targeting well-characterized biology and pathways.
Arcus Biosciences (RCUS) reported Q3 2021 results, showing a net loss of $78 million, a significant decline from net income of $1.8 million in Q3 2020. Collaboration revenues dropped to $9.5 million vs. $64.5 million year-over-year. Cash and investments rose to $743 million, providing funding through at least 2023. Gilead is reviewing an opt-in for Arcus's anti-TIGIT program, potentially yielding a $275 million payment. The ARC-7 study showed superior efficacy for domvanalimab combinations in non-small cell lung cancer. However, R&D expenses surged, raising concerns about financial sustainability.
Arcus Biosciences, Inc. (NYSE:RCUS) announced it will report its financial results and corporate update for Q3 2021 on November 8, 2021, after market close. The company focuses on developing innovative molecules and combination therapies for cancer treatment, working on five investigational medicines targeting pathways like TIGIT and PD-1. Founded in 2015, Arcus aims to expedite the development of first or best-in-class cancer therapies through collaboration with industry partners, patients, and physicians.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company, announced the grant of stock options to six new employees. These options total 48,800 shares at an exercise price of $34.38, based on the closing price from October 25, 2021. The stock options were issued under the 2020 Inducement Plan approved by the Board of Directors in January 2020. The company continues to develop innovative cancer therapies, with five molecules currently in clinical development targeting significant unmet needs in oncology.
Arcus Biosciences (NYSE:RCUS) has granted stock options to eight new employees, totaling 66,400 shares at an exercise price of $31.48 per share, reflecting the closing price on October 8, 2021. This grant was made under the Company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing cancer therapies, with five molecules currently in clinical trials, including Etrumadenant and Quemliclustat, addressing various cancer types. The company aims to meet significant unmet medical needs in oncology.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options to eight new employees, allowing them to purchase a total of 58,200 shares at $36.99 each, the closing price on September 23, 2021. This action is part of the 2020 Inducement Plan approved by the Board. The company is focused on oncology and has five clinical molecules in development, including Etrumadenant, Quemliclustat, and Domvanalimab, targeting various cancers with innovative therapies.
Arcus Biosciences, Inc. (NYSE: RCUS) has granted five new employees options to purchase a total of 44,200 shares at an exercise price of $34.31, reflecting the closing price on September 8, 2021. This grant is part of the Company's 2020 Inducement Plan, approved by the Board in January 2020, in compliance with NYSE regulations. Arcus focuses on developing innovative cancer therapies, with five molecules currently in clinical development addressing significant unmet medical needs.
Arcus Biosciences (NYSE:RCUS) announced its upcoming presentations at two virtual investor conferences in September 2021. The Citi’s 16th Annual Virtual Biopharma Conference will take place on September 10 at 1:25 pm ET, followed by the 2021 Cantor Virtual Global Healthcare Conference on September 27 at 4:40 pm ET. Investors can access a live audio webcast through the company’s website, with a replay available for two weeks post-event. Arcus focuses on developing innovative cancer therapies, currently advancing five molecules in clinical trials.
Arcus Biosciences (NYSE:RCUS) has granted stock options for 104,200 shares to twelve new employees at an exercise price of $29.35, reflecting the closing price on August 23, 2021. This grant is part of the 2020 Inducement Plan approved in January 2020, under NYSE Manual Rule 303A.08. The company is dedicated to developing innovative cancer therapies and currently has five drugs in clinical development, including Etrumadenant and Quemliclustat, targeting various cancer types.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options for 30,400 shares to four new employees. The options are priced at $28.24 per share, equivalent to the closing price on August 9, 2021. This issuance falls under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies, with five molecules currently in clinical development targeting various oncology indications.